FDA Approves Aducanumab for Treatment of Alzheimer’s Disease
Last month, Aducanumab (Aduhelm™) was approved as a treatment for Alzheimer’s Disease by the U.S. Food and Drug Administration (FDA). This is the first FDA-approved therapy to potentially delay decline from the disease, compared to current medications that only address symptoms.
Read More













